Literature DB >> 1469694

Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors.

G D Hartman1, M S Egbertson, W Halczenko, W L Laswell, M E Duggan, R L Smith, A M Naylor, P D Manno, R J Lynch, G Zhang.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1469694     DOI： 10.1021/jm00102a020

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  39 in total

1.  Structural analysis of the KGD sequence loop of barbourin, an alphaIIbbeta3-specific disintegrin.

Authors:  H Minoux; C Chipot; D Brown; B Maigret
Journal:  J Comput Aided Mol Des       Date:  2000-05       Impact factor: 3.686

2.  Strategies for the determination of pharmacophoric 3D database queries.

Authors:  J H Van Drie
Journal:  J Comput Aided Mol Des       Date:  1997-01       Impact factor: 3.686

Review 3.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Computer-aided drug design: the next 20 years.

Authors:  John H Van Drie
Journal:  J Comput Aided Mol Des       Date:  2007-11-08       Impact factor: 3.686

5.  Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller.

Authors:  Ramesh B Basani; Hua Zhu; Michael A Thornton; Cinque S Soto; William F Degrado; M Anna Kowalska; Joel S Bennett; Mortimer Poncz
Journal:  Blood       Date:  2008-11-05       Impact factor: 22.113

Review 6.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

7.  LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Authors:  Shizhen Zhu; Xiaoling Zhang; Nina Weichert-Leahey; Zhiwei Dong; Cheng Zhang; Gonzalo Lopez; Ting Tao; Shuning He; Andrew C Wood; Derek Oldridge; Choong Yong Ung; Janine H van Ree; Amish Khan; Brittany M Salazar; Edroaldo Lummertz da Rocha; Mark W Zimmerman; Feng Guo; Hong Cao; Xiaonan Hou; S John Weroha; Antonio R Perez-Atayde; Donna S Neuberg; Alexander Meves; Mark A McNiven; Jan M van Deursen; Hu Li; John M Maris; A Thomas Look
Journal:  Cancer Cell       Date:  2017-08-31       Impact factor: 31.743

Review 8.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 9.  Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area.

Authors:  Xu Ran; Jason E Gestwicki
Journal:  Curr Opin Chem Biol       Date:  2018-06-13       Impact factor: 8.822

10.  A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.

Authors:  G P Camenisch; W Wang; B Wang; R T Borchardt
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.